Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q29983 (MIC)
 21,138 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The in vitro activity of ofloxacin (Hoe 280) against Staphylococcus aureus, some Enterobacteriaceae and Pseudomonas spp. is compared with that of gentamicin using the agar dilution method to determine the minimal inhibitory concentration of each agent for the isolates. Ofloxacin and gentamicin were found to have similar activity against Staphylococcus aureus with an MIC50 of 0.25 mg/l and an MIC90 of 1.0 mg/l. However, ofloxacin appears to be more active against the Enterobacteriaceae than gentamicin with lower MICs for some species of that family. Ofloxacin was found to have an MIC50 value of 0.25 mg/l for the Enterobacteriaceae and an MIC90 of 1.0 mg/l while the MIC90 of gentamicin for the same isolates was 32.0 mg/l. A significant proportion of our Pseudomonas spp. were resistant to gentamicin with an MIC90 of over 16 mg/l and a range of 0.5 mg/l to greater than 128 mg/l. Ofloxacin had an MIC range of 0.25 to 4.0 mg/l for the same organisms.
Infection 1986
PMID:Comparison of the in vitro activity of ofloxacin and gentamicin against isolates from hospitalised patients. 346 54

Niridazole, a nitrothiazole derivative, demonstrated powerful antimicrobial activity against 510 clinical isolates of Gardnerella vaginalis tested. MIC's ranged from 0.002 to 1.0 mg/l with MIC50 and MIC90 values of 0.02 and 0.067 mg/l respectively.
Infection
PMID:Antimicrobial effects of niridazole on Gardnerella vaginalis. 349 79

The clinical efficacy, tolerability and safety of imipenem/cilastatin were studied in a open, prospective trial with 63 general surgical patients suffering from bacterial infections. According to study criteria, 48 of the patients were evaluable. Clinical cure was achieved in 47 of these 48 patients (97.9%). The causative organisms were eliminated in 39 of the 47 patients cured. Clinical side-reactions were observed in 4.2% of the 63 patients treated. In 8.3% of these laboratory parameters were changed. 77 of the 78 microorganisms isolated before therapy were sensitive to imipenem (MICs 0.02-2.0 mg/l). In one patient a coagulase-negative staphylococcus with an MIC of 16 mg/l was isolated after five days of therapy.
Infection 1986
PMID:[Effect and tolerance of daily 2 X 1 g imipenem/cilastatin in general surgery]. 353 Oct 26

In this study, we compared the activity of pefloxacin, enoxacin and ciprofloxacin against 269 enteropathogenic strains (Campylobacter jejuni, enteropathogenic Escherichia coli, Salmonella typhi, Shigella spp., Vibrio cholerae and Yersinia enterocolitica) with that of rosoxacin, flumequin, nifuroxazide, erythromycin, chloramphenicol, ampicillin, cefotaxime, tetracycline, amikacin, netilmicin, sulfamethoxazole, trimethoprim and co-trimoxazole. Pefloxacin, enoxacin and ciprofloxacin were always among the most active compounds. Furthermore, resistant strains or strains with elevated MIC values were not found. The MIC90 value for these three compounds was less than or equal to 0.25 mg/l, except for C. jejuni where it was 0.3 mg/l and 1.4 mg/l for pefloxacin and enoxacin, respectively.
Infection
PMID:The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms. 354 45

Strain SLCC 4013 of Listeria monocytogenes is susceptible in vitro to ampicillin (MIC 0.5 mg/l) as well as to gentamicin (MIC 0.5 mg/l). Whereas treatment of mice infected with this virulent strain with 0.5 mg ampicillin twice a day resulted in a marked decrease in bacterial counts per spleen, the administration of 2 mg gentamicin twice a day hardly reduced bacterial multiplication. The combination of both drugs was not much more effective than ampicillin alone. Thus, a synergistic effect of both these antibiotics on intracellularly growing bacteria could not be demonstrated.
Infection
PMID:Lack of synergism of ampicillin and gentamicin in experimental listeriosis. 357 Apr 81

The antimicrobial susceptibility of 195 recent clinical isolates of anaerobic bacteria was studied to ampicillin alone, ampicillin + 1 mg/l sulbactam, ampicillin + 5 mg/l sulbactam, and cefoxitin by means of agar dilution tests. The ampicillin-sulbactam combinations were the most effective drugs against species of the Bacteroides fragilis group, the MIC90 of ampicillin + 5 mg/l sulbactam for B. fragilis being less than 1 mg/l, compared to 256 mg/l of ampicillin, 4 mg/l of ampicillin + 1 mg/l sulbactam, and 8 mg/l of cefoxitin. No significant difference between ampicillin alone and in combination with sulbactam was observed against gram-positive anaerobic rods, Peptococcus spp. and Peptostreptococcus spp. with MIC's less than 2 mg/l.
Infection 1987
PMID:In vitro activity of ampicillin plus sulbactam against anaerobes compared to ampicillin and cefoxitin. 369 11

Twenty clinical isolates of Staphylococcus aureus, resistant to both gentamicin and methicillin, were tested in vitro for sensitivity to rifampicin, novobiocin, fusidic acid, vancomycin, teicoplanin and an extended range of aminoglycosides. Rifampicin was the most active compound tested, having an MIC of less than 0.02 mg/l. All the strains were inhibited by 1 mg/l of novobiocin, vancomycin and teicoplanin, and only one strain was resistant to fusidic acid. 50% of the strains were inhibited by less than 1 mg/l of amikacin and netilmicin, but other aminoglycosides were of poor activity. Resistant mutants were selected when strains were grown in the presence of rifampicin, novobiocin or fusidic acid alone, but this did not occur when rifampicin was combined with either novobiocin or vancomycin. Pharmacokinetic and other considerations suggest that a combination of rifampicin and novobiocin deserves further assessment for the treatment of infections caused by this type of organism.
Infection
PMID:In vitro activity of combinations of antibiotics against Staphylococcus aureus resistant to gentamicin and methicillin. 384 15

Imipenem-cilastatin was given in doses of 1 g intravenously every 6 h to 31 patients. Twenty-five patients, with 27 infections, were clinically evaluable and received 20 to 210 g of imipenem for a duration of 5 to 56 days (average 16.3 days). Infections included seven cases of osteomyelitis, seven of bacteremia, five of cellulitis, two of pneumonia, three of pelvic cellulitis, two of intraabdominal abscess, and one each of empyema, mediastinitis, and endometritis. Fifty-five percent of the infections were caused by gram-negative bacilli, 33% were due to gram-positive organisms, and 10% were caused by anaerobes. Twenty-two patients (81%) were cured, three improved, one relapsed, and one became superinfected with a resistant organism. In 5 of 11 cases with Pseudomonas aeruginosa, the imipenem MIC for organisms isolated by the end of treatment was higher than it was initially, raising concern that imipenem should not be used alone to treat Pseudomonas aeruginosa infections. Twenty-one patients had no adverse reaction; of the remaining 10 patients, 4 had nausea, 1 had urticaria, and 6 had mild abnormalities in hepatic function; three episodes of diarrhea included two with Clostridium difficile toxin in stool and one with pseudomembranous colitis, as determined by sigmoidoscopy. Levels of creatinine, hemoglobin, leukocytes, platelets, prothrombin, and urine components were unchanged. Imipenem-cilastatin is a clinically effective antibiotic with freedom from nephrotoxicity and hematological abnormalities in the large doses used in this study.
 ...
PMID:Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients. 386 Jan 87

A 51-year-old male patient with diabetes mellitus complicated by ketoacidotic imbalance developed a rhinocerebral mucor mycosis that advanced despite early amphotericin B therapy and extensive surgical intervention. The MIC of amphotericin B for the isolated mucor species was 64 mg/l, meaning that in vitro resistance also existed. Only long-term treatment with ketoconazole (600 mg/day, perorally) was successful in curing the disease.
Infection
PMID:An amphotericin B-resistant case of rhinocerebral mucor mycosis. 392 96

The in vitro activity of cefpirome, a new cyclopyridinium cephalosporin, was evaluated against 947 aerobic and anaerobic bacteria. Cefpirome inhibited 90% of Escherichia coli, Klebsiella spp., Citrobacter diversus, Morganella morganii, Proteus vulgaris, Proteus mirabilis, Aeromonas spp., Salmonella spp., Shigella spp. and Haemophilus and Neisseria species at less than or equal to 0.4 mg/l. It had activity comparable to that of cefotaxime, ceftizoxime, ceftazidime, aztreonam, and moxalactam against these species. Only a few Citrobacter freundii, Enterobacter spp. and Serratia marcescens had MICs above 3.1 mg/l. The activity of cefpirome against Pseudomonas aeruginosa, 90% MIC of 12.5 mg/l, was superior to piperacillin, moxalactam, cefotaxime and cefoperazone. The 90% MIC against Staphylococcus aureus was 0.8 mg/l, but methicillin-resistant staphylococci were not inhibited. Cefpirome was not significantly hydrolyzed by most plasmid beta-lactamases (TEM, SHV-1, PSE, OXA) nor by chromosomal enzymes (P99, Branhamella catarrhalis, K1). Cefpirome did not inhibit chromosomal or plasmid beta-lactamases. Mice systemically infected with E. coli, Klebsiella pneumoniae, P. aeruginosa and S. aureus were protected by concentrations of cefpirome ranging from 0.85 mg/kg for K. pneumoniae to 4.467 mg/kg for P. aeruginosa.
Infection
PMID:The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa. 392 97


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>